Mouse IGFBP-1 Antibody

The insulin-like growth factor binding protein (IGFBP) family consists of six structurally related proteins that bind IGF with high affinity (1, 2). These proteins share conserved cysteine-rich N- and C- terminal regions that participate in IGF binding. IGFBPs regulate the bioavailability of IGFs and modulate their biological activities, both positively and negatively. Some IGFBPs also have intrinsic bioactivity that is IGF-independent. Post-transitional modifications of the IGFBPs, including glycosylation, phosphorylation and proteolysis, influence IGF binding affinities and tissue localization, affecting both the IGF-dependent and independent functions (1, 2).

Mouse IGFBP-1 cDNA encodes a 272 amino acid (aa) residue precursor protein with a putative 25 aa signal peptide (3). Mature mouse IGFBP-1 contains potential phosphorylation and proteolytic cleavage sites, an Arg-Gly-Asp (RGD) integrin receptor recognition sequence, but lacks potential N-linked glycosylation sites. IGFBP‑1 binds equally well to IGF-I and IGF-II. Phosphorylation of human IGFBP-1, but not rat IGFBP-1, increases IGF affinity. Mouse IGFBP-1 shares 67% and 93% aa sequence identity with human and rat IGFBP-1, respectively. IGFBP-1 is expressed in liver, decidua, and kidneys and is the most abundant IGFBP in amniotic fluid. Hepatic production of IGFBP-1 is down-regulated by insulin and up-regulated by glucocorticoids. Circulating IGFBP-1 levels are elevated under various catabolic conditions including bacterial or viral infections, trauma and diabetes (4). IGFBP-1 has been shown to either potentiate or inhibit the activities of IGF in a variety of cells. IGFBP-1, through its RDG motif, also interacts with alpha5 beta1 intergrin to stimulate changes in cell adhesion and migration in the absence of IGFs (1, 2).